CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Cyclosporine 0.05% Ophthalmic Emulsiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02554981
NCT02554981Phase 4Completed
CompareCT.gov

Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER)

Allergan·interventional·Posted Sep 21, 2015·Updated Jun 1, 2017

In Brief

A Phase 4 clinical trial evaluating Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye Syndromes. Completed, enrolled 51 participants across 2 sites.

Detailed Summary

This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 21, 2015
Enrollment StartJul 21, 2015
Primary CompletionMar 24, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.8 years ago

Interventions

Cyclosporine 0.05% Ophthalmic Emulsiondrug

Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.